Specialty Pharmacy

Based on overall response rate, acalabrutinib in tablet form is now FDA approved for all approved indications, enabling co-administration alongside a proton pump inhibitor.

Dalteparin sodium (Fragmin) is indicated for the extended treatment of symptomatic venous thromboembolism (VTE) to reduce VTE recurrence in adult patients with cancer, as well as several other indications.

The median overall survival of the lenvatinib monotherapy arm is longer than that observed in previous clinical trials evaluating it as a monotherapy for unresectable hepatocellular carcinoma.

Receiving a human papillomavirus vaccine and local surgical treatment could reduce the risk of recurring cervical lesions by 57%.

The FDA approved a new drug that treats unresectable and metastatic HER2-low breast cancer, giving patients with this new subtype a treatment beyond chemotherapy.

Patients can better understand the most current recommendations for breast cancer screening with the new NCCN Guidelines for Patients®: Breast Cancer Screening and Diagnosis.

Electronic symptom self-measuring provided early detection of toxic effects and helped anticipate necessary medical interventions for pediatric patients with cancer.

Case management programs or pharmacist-delivered high-touch care are critical components in medical specialty drug management.

Gamma-delta T-cells undergo a biochemical change that leads them to spur the growth of tumors that previously restricted.

Pharmacists have the potential to help optimize treatment and maximize supportive care management for targeted therapies.

Over the next few years, undiagnosed breast cancer cases may add to the demand for more rigorous end-stage treatments and therapeutics.

Studies suggest novel immunotherapy may have efficacy as monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.

Ustekinumab is the first and only biologic that targets both cytokines interleukin (IL)-12 and IL-23.

Many companies overlook the power that workplace culture can have on employee wellness and instead, focus relentlessly on financial metrics.

The findings of the phase 1b/2 CHRYSALIS-2 cohort will be presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer.

Study shows that adult survivors of cancer had a 42% greater risk of CVD than people who did not have the disease.

Currently, there is no treatment targeted for superoxide dismutase 1 amyotrophic lateral sclerosis, which has a life expectancy of 3 to 5 years from time of symptom onset.

The drug combination demonstrated a 64.5% confirmed objective response rate in individuals with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy.

The FDA is evaluating the use of adagrasib (MRTX849) to treat patients with non-small cell lung cancer harboring a KRAS G12C mutation who have previously received at least 1 systemic therapy.

Belimumab (Benlysta) the first FDA-approved therapy for pediatric lupus nephritis.

Pirtobrutinib is under investigation in clinical trials in patients with CLL/small lymphocytic lymphoma, mantle cell lymphoma, and non-Hodgkin lymphoma.

The number of medical visits carried out via telehealth grew from 840,000 in 2019 to 52.7 million in 2020.

FDA accepts supplemental Biologics License Application for Hyrimoz HCF, a biosimilar with the same indications as adalimumab (Humira).

Trastuzumab deruxtecan is an engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

The numbers dropped sharply in March 2020 from before the pandemic among men who have sex with men and individuals who inject drugs.

From a patient perspective, the lack of awareness of biosimilars is the biggest barrier to adoption.

People living with psoriatic arthritis deserve to be informed about ways to approach disease management holistically and with a personalized approach.

Delayed diagnosis in younger individuals and presentation of advanced disease highlights need for awareness.

Progression-free survival was longer with brentuximab vedotin and fewer patients with Hodgkin lymphoma in this group received subsequent therapy.

Tapinarof is a first-in-class topical steroid-free aryl hydrocarbon receptor antagonist intended to mitigate the symptoms of plaque psoriasis.